Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
about
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues.Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenograftsNovel treatments and therapies in development for pancreatic cancer.Somatostatin analogs and radiopeptides in cancer therapy.Biotherapeutic approaches to pancreatic cancer.Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer.Somatostatin receptors in the gastrointestinal tract in health and diseaseA randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae.Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo resultsA review of the use of somatostatin analogs in oncologySomatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.Tumors of the endocrine/neuroendocrine system: an overview.Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues.Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study.Systemic and adjuvant therapy for patients with pancreatic carcinoma.Alternative therapeutic options in patients with advanced gastrointestinal cancer.Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters.Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas.Effects of sandostatin, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters.
P2860
Q33753449-F0FE727E-DC08-40E3-BDE4-ABC0C86EC265Q34091373-FA29EE32-1866-41E9-978C-E1F8A8DFFEF4Q34378050-9030AB33-C291-41F8-BC08-B93D050120B3Q34605758-15A09088-5427-4DAB-8462-75DD68B4E426Q34660844-FAEE7616-4AC0-4E9A-9D3D-607B331FBDC6Q34972896-3839F976-8313-40B9-AD12-8367F8892C89Q35093628-DC25C020-3C43-41ED-A028-66DF94FC3164Q35130509-6BCBC75A-0652-4B6A-BA52-BB78D571EA87Q35241625-C368B18B-8116-428B-8882-072E63EF82A9Q36079892-FE8F29AC-B46C-455D-8810-0988F98C9BF8Q36114875-630178CF-7130-4AF5-B6EB-274C644FBB63Q36116318-BAB86822-E507-4BF3-82FC-1B482AD285B5Q36295053-53096362-F4A1-4F76-86B6-50273608EA30Q36618155-0E402BAD-72DD-459A-A6AA-FA8D51A98DEEQ36833161-5278EFB8-221A-4D97-A7B2-6398F03F7122Q37564373-A43476BF-ED0C-4E2E-ABF2-97B316C55095Q37898112-8B81DE43-F54A-4875-9B97-CA83FA5934C0Q38344542-727B9D42-361F-4DFA-8166-298E81A6C437Q40623008-84DB8E3D-A4E9-40A6-8956-BFBD91B1D7F3Q40642381-8CA9FB13-FBB9-4976-8ABD-384093572B8BQ40835915-CB1D0F8B-D688-4DCA-AC88-B89920355BAFQ41016245-BDF5F153-4D32-407D-819E-FBBD99EC661BQ42590309-9978EEE6-693C-4DC0-A0EC-305D9704899EQ46540777-FCD3836A-2FC2-442F-8E9D-987FF0211595Q47213665-981A5280-C4F9-48B6-B723-CC1C293B4740Q49057589-EA61533C-45E5-461A-BE2A-9A388221D16A
P2860
Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
description
1990 nî lūn-bûn
@nan
1990 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
name
Treatment of patients with met ...... y including endocrine effects.
@ast
Treatment of patients with met ...... y including endocrine effects.
@en
type
label
Treatment of patients with met ...... y including endocrine effects.
@ast
Treatment of patients with met ...... y including endocrine effects.
@en
prefLabel
Treatment of patients with met ...... y including endocrine effects.
@ast
Treatment of patients with met ...... y including endocrine effects.
@en
P2093
P2860
P356
P1476
Treatment of patients with met ...... y including endocrine effects.
@en
P2093
Foekens JA
Lamberts SW
Planting AS
Portengen H
P2860
P2888
P304
P356
10.1038/BJC.1990.343
P407
P577
1990-10-01T00:00:00Z
P5875
P6179
1010026977